원문정보
초록
영어
We have generated neutralizing monoclonal antibodies directly from human B-cells of convalescent patients who had been infected with a new H1N1 virus. The generated antibodies could neutralize various A type influenza viruses and were efficacious in animal survival tests. One antibody, CT120, from the first screening using hemagglutinin (HA) of H1N1 showed microneutralization (MN) activity against H1, H2, H5, and H9 of group 1. Another antibody, CT149, from the second screening using HA of H3N2 from the same antibody pool showed MN activity against H1, H5, and H9 of group 1 and H3 and H7 of group. Interestingly this antibody could neutralize H3N2 isolates over the past 40 years. These antibodies cannot inhibit hem-agglutination induced by HA, but can inhibit HA associated cell fusion which indicate that these antibodies are targeting the stem region of HA. Animal passive protection test indicated that CT120 was effective prophylactically and therapeutically against H1N1 and H5N1. CT149 was also effective in prophylactically and therapeutically against H3N2. Taken together, the aforementioned two neutralizing monoclonal antibodies can be useful prophylactic and therapeutic agents against epidemic and pandemic influenza virus infection. This work was performed mainly under the collaboration of Dr. Ruben Donis (Chief, Molecular Virology and Vaccines Branch, Influenza Division, CDC, Atlanta, GA USA).